These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine in healthy adolescents in Korea--A randomised trial. Lee HJ; Choe YJ; Hong YJ; Kim KH; Park SE; Kim YK; Oh CE; Lee H; Song H; Bock H; Casula D; Bhusal C; Arora AK Vaccine; 2016 Feb; 34(9):1180-6. PubMed ID: 26826544 [TBL] [Abstract][Full Text] [Related]
66. Approach to the Discovery, Development, and Evaluation of a Novel Neisseria meningitidis Serogroup B Vaccine. Green LR; Eiden J; Hao L; Jones T; Perez J; McNeil LK; Jansen KU; Anderson AS Methods Mol Biol; 2016; 1403():445-69. PubMed ID: 27076147 [TBL] [Abstract][Full Text] [Related]
67. Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease. Kaaijk P; van Straaten I; van de Waterbeemd B; Boot EP; Levels LM; van Dijken HH; van den Dobbelsteen GP Vaccine; 2013 Feb; 31(7):1065-71. PubMed ID: 23273968 [TBL] [Abstract][Full Text] [Related]
68. Molecular characterization of invasive serogroup B Neisseria meningitidis isolates from Spain during 2015-2018: Evolution of the vaccine antigen factor H binding protein (FHbp). Abad R; García-Amil C; Navarro C; Martín E; Martín-Díaz A; Vázquez JA J Infect; 2021 Apr; 82(4):37-44. PubMed ID: 33610688 [TBL] [Abstract][Full Text] [Related]
69. Understanding immunogenicity assessments for meningococcal serogroup B vaccines. Balmer P; Beeslaar J; Findlow J; Srivastava A Postgrad Med; 2020 Mar; 132(2):184-191. PubMed ID: 32124678 [TBL] [Abstract][Full Text] [Related]
70. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis. Norheim G; Aase A; Caugant DA; Høiby EA; Fritzsønn E; Tangen T; Kristiansen P; Heggelund U; Rosenqvist E Vaccine; 2005 May; 23(29):3762-74. PubMed ID: 15893613 [TBL] [Abstract][Full Text] [Related]
71. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Marshall HS; Richmond PC; Nissen MD; Wouters A; Baber J; Jiang Q; Anderson AS; Jones TR; Harris SL; Jansen KU; Perez JL Vaccine; 2013 Mar; 31(12):1569-75. PubMed ID: 23352429 [TBL] [Abstract][Full Text] [Related]
72. Serum Bactericidal Antibody Responses of Adults Immunized with the MenB-4C Vaccine against Genetically Diverse Serogroup B Meningococci. Giuntini S; Lujan E; Gibani MM; Dold C; Rollier CS; Pollard AJ; Granoff DM Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27847367 [TBL] [Abstract][Full Text] [Related]
73. Differential capacities of outer membrane proteins from Neisseria meningitidis B to prime the murine immune system after vaccination. Silva Junior FC; Gioia CA; Oliveira JM; Cruz SC; Frasch CE; Milagres LG Scand J Immunol; 2007 Jan; 65(1):1-7. PubMed ID: 17212760 [TBL] [Abstract][Full Text] [Related]
74. Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Finney M; Vaughan T; Taylor S; Hudson MJ; Pratt C; Wheeler JX; Vipond C; Feavers I; Jones C; Findlow J; Borrow R; Gorringe A Hum Vaccin; 2008; 4(1):23-30. PubMed ID: 17921703 [TBL] [Abstract][Full Text] [Related]
75. Meningococcal factor H-binding protein vaccines with decreased binding to human complement factor H have enhanced immunogenicity in human factor H transgenic mice. Rossi R; Granoff DM; Beernink PT Vaccine; 2013 Nov; 31(46):5451-7. PubMed ID: 24035433 [TBL] [Abstract][Full Text] [Related]
77. Human B Cell Responses to Dominant and Subdominant Antigens Induced by a Meningococcal Outer Membrane Vesicle Vaccine in a Phase I Trial. Rollier CS; Dold C; Marsay L; Linder A; Green CA; Sadarangani M; Norheim G; Derrick JP; Feavers IM; Maiden MCJ; Pollard AJ mSphere; 2022 Feb; 7(1):e0067421. PubMed ID: 35080470 [TBL] [Abstract][Full Text] [Related]
78. Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1. Brunelli B; Del Tordello E; Palumbo E; Biolchi A; Bambini S; Comanducci M; Muzzi A; Pizza M; Rappuoli R; Donnelly JJ; Giuliani MM; Serruto D Vaccine; 2011 Jan; 29(5):1072-81. PubMed ID: 21130753 [TBL] [Abstract][Full Text] [Related]
79. Cross-reactivity of 4CMenB vaccine-induced antibodies against meningococci belonging to non-B serogroups in Italy. Fazio C; Biolchi A; Neri A; Tomei S; Vacca P; Ambrosio L; Palmieri A; Mori E; La Gaetana R; Pizza M; Giuliani MM; Serino L; Stefanelli P Hum Vaccin Immunother; 2021 Jul; 17(7):2225-2231. PubMed ID: 33522380 [TBL] [Abstract][Full Text] [Related]
80. Improved immunogenicity of a H44/76 group B outer membrane vesicle vaccine with over-expressed genome-derived Neisserial antigen 1870. Koeberling O; Welsch JA; Granoff DM Vaccine; 2007 Feb; 25(10):1912-20. PubMed ID: 16677743 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]